Article
Urology Times asked Maha H. Hussain, MD: How will the advent of PARP inhibitors change the management of advanced prostate cancer?
Urology Times asked Maha H. Hussain, MD: How will the advent of PARP inhibitors change the management of advanced prostate cancer?
For more on PARP inhibitors, see: PARP inhibitor significantly extends rPFS vs. hormonal therapy
More videos:
Focal therapy vs. surveillance for low-risk PCa
Medicare final rule: Changes affect cysto, prostate Bx reimbursement
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.